Investors look for better efficacy from safe cancer immunotherapies
This article was originally published in Scrip
Executive Summary
Company executives and biotech investors are very grateful for the way that Seattle-based Dendreon has paved the way for other cancer vaccines and immunotherapies. While it is still uncertain that the Provenge vaccine for metastatic castrate-resistant prostate cancer and its $93,000 price tag will ever be seen as a significant medical intervention or a commercial success, Dendreon's pioneering journey through both the technical and regulatory space is appreciated widely.